natgillin/translations-raw huggingface dataset:
The polypeptide or the polynucleotide sequence or the host cell according to embodiment 1 for the use according to embodiment 1 wherein said disorder affects the alimentary canal, a section of the alimentary canal, the liver, liver cells, epithelial cells, epidermal cells, neuronal cells kidneys, spleen, lungs, heart, the pancreas, and/or pancreatic cells. The polypeptide or the polynucleotide sequence or the host cell according to embodiment 1 for the use according to embodiment 1 wherein said disorder is selected from the group consisting of inflammatory bowel disorder (IBD), colitis, rheumatoid arthritis, psoriasis, multiple sclerosis, type I diabetes, coeliac disease, atopic dermatitis, rhinitis, irritable bowel syndrome (IBS), ulcerative colitis, pouchitis, Crohn's disease, functional dyspepsia, atopic diseases, necrotising enterocolitis, non alcoholic fatty liver disease, gastrointestinal infection Lupus, nephritis/glomerulonephritis, asthma, COPD, mycocarditis and combinations thereof. 
Polipeptid ili polinukleotidna sekvenca prema zahtjevu 1 za upotrebu prema zahtjevu 1 naznačen time da navedeni poremećaj pogađa alimentarni kanal, dio alimentarnog kanala, jetru, stanice jetre, epitelne stanice, epidermalne stanice, neuronalne stanice bubrega, slezenu, pluća, srce, pankreas, i/ili stanice gušterače, ili pri čemu se navedeni poremećaj bira iz skupine koja se sastoji od upalnog poremećaja crijeva (IBD), kolitisa, reumatoidnog artritisa, psorijaze, multiple skleroze, dijabetesa tipa I, celijakije, atopijskog dermatitisa, rinitisa, sindroma iritablinog crijeva (IBS), ulceroznog kolitisa, pouchitisa, Crohnove bolesti, funkcionalne dispepsije, atopijskih bolesti, nekrozirajućeg enterokolitisa, ne-alkoholne bolesti masne jetre, gastrointestinalne infekcije, Lupusa, nefritisa/glomerulonefritisa, astme, KOPB, mikokarditisa i njihovih kombinacija.
determining the paternal genome is homozygous for the respective first allele at each loci of the first plurality and determining the maternal genome is homozygous for the respective second allele at the same locus. 
određivanje očinskog genoma je homozigotno za odgovarajući prvi alel; i određivanje majčinskog genoma je homozigotno za odgovarajući drugi alel.
A product according to claim 9 wherein 1% to 50% of the total sialylation is a2, 6-sialyation, and 50% to 99% of the total sialylation is a 2,3- sialyation 
Proizvod za uporabu prema bilo kojem prethodnom zahtjevu, naznačen time da rekombinantni FSH dobiven iz ljudske stanične linije sadrži 02, 3- 1 02, 6-sijalinizaciju, pri čemu je od 1% do 99% ukupne sijalinizacije 02,3-sijalinizacija i od 1% do 99% ukupne sijalinizacije je 02,6-sijalinizacija.
The preparation method according to claim 9, wherein the organic solvent is selected from the group consisting of ethanol, methanol and n-butanol. A pharmaceutical composition comprising the compound of general formula (I) according to claim 1 as the active ingredient and a pharmaceutically acceptable carrier, adjuvant or diluent. 
Farmaceutski sastav za korištenje u liječenju bolesti povezanih s abnormalnim aktivnostima JAK3 i/ili JAK1 kinaza, obuhvaćajući spoj opće formule (I) prema zahtjevu 1 kao aktivan sastojak i farmaceutski prihvatljiv nosač, pomoćno sredstvo ili razrjeđivač.
A composition comprising at least two compounds selected from D-Sorbitol; Baclofen; Pilocarpine; Naltrexone; Methimazole; Mifepristone, and Ketoprofen or salts thereof, for simultaneous, separate or sequential administration for use in the treatment of Charcot-Marie Tooth disease (CMT), or a related disorder selected from hereditary neuropathy with liability to pressure palsies (HNPP), Dejerine-Sottas syndrome (DSS) and congenital hypomyelinating neuropathy (CHN). 
Smjesa koja sadrži barem dva spoja izabrana između D-sorbitola; baklofena; pilokarpina; naltreksona; metimazola; mifepristona, i ketoprofena ili njihovih soli, za istodobnu, zasebnu ili sekvencijsku primjenu za uporabu u liječenju Charcot-Marie Tooth (CMT) bolesti, ili srodnog poremećaja izabranog između nasljedne neuropatije sa sklonošću kljenuti na pritisak (HNPP), Dejerine-Sottas sindroma (DSS) i kongenitalne hipomijelinizirajuće neuropatije (CHN).
The container of claim 22 or 23, comprising from about 20 mg to about 400 mg of levofloxacin, preferably about 28 mg to about 280 mg of levofloxacin, at least about 100 mg of levofloxacin, or at least about 400 mg of levofloxacin. 
Posuda iz patentnog zahtjeva 22 ili 23, obuhvaća od oko 20 mg do oko 400 mg levofloksacina, preporučljivo oko 28 mg do oko 280 mg levofloksacina, najmanje oko 100 mg levofloksacina, ili najmanje oko 400 mg levofloksacina.
The present invention also provides the following process for the manufacture of the compound with Formula I. 
Ovaj izum također osigurava proces za priređivanje spoja s formulom I.
The compound of formula (I-C) wherein: 
Spoj, naznačen time, da ima formulu (I-C):
The composition according to claim 21, wherein said effective amount is about 0.001-50 mg/kilogram of said cells, tissue, organ or animal. 
(i) pri čemu je navedena učinkovita količina oko 0,001-50 mg/kilogramu navedenih stanica, tkiva, organa ili životinja; HR P20190220 T1
The composition of claim 3, comprising 40-60% (w/w) carbohydrates obtainable from carob, and 40-60% (w/w) carbohydrates obtainable from apple, wherein the percentages are based on the dry matter. 
Pripravak u skladu s patentnim zahtjevom 2, naznačen time što sadrži 40-60% (tež./tež.) ugljikohidrata koji se mogu dobiti iz rogača, te 40-60% (tež./tež.) ugljikohidrata koji se mogu dobiti iz jabuke, gdje se postoci baziraju na suhoj tvari.
Use of nanoparticles or nanoparticles' aggregates for the preparation of a pharmaceutical composition for use in a method of altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Uporaba nanočestica HfO2 ili agregata nanočestica HfO2 za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO2 ili gustoća spomenutih agregata nanočestica HfO2 barem 7 g/cm3, i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 i 7,5 u fiziološkoj tekućini.
The controlled evacuation ostomy appliance of claim 1, further comprising a stoma seal support attached to the stoma seal. 
Kontrolirani evakuacijski ostomijski uređaj prema zahtjevu 1, naznačen time da nosač stoma brtve uključuje član smješten unutar prvog otvora.
A toothbrush (10) according to claim 3 characterized in that all the spines (16,17,18) meet adjacent to the first and second ends (12,13) of the handle (11). 
Četkica za zube (10), u skladu s patentnim zahtjevom 2, naznačena time što se sve prečke (16, 17, 18) sreću uz prvi i drugi kraj (12, 13) drške (11).
at least one water swelling anionic polymer and the resulting tablet providing a pH-dependent release characteristic with a faster release characteristic in the range of pH < 4.5, and a slower and further on pH-independent release characteristic in the range from pH 4.5 to 7.5. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 1, naznačena time, da rezultirajuća tableta osigurava pH-ovisno oslobađanje karakterizirano bržim oslobađanjem karakterističnim u rasponu pH < 4.5, te sporijim i nadalje pH-neovisnim oslobađanjem karakterističnim u rasponu od pH 4.5 do 7.5.
The process according to any one of claims 1 to 4, wherein step d) comprises a mechanical treatment according to claim 5 or 6 and a treatment with one or more chemical agents according to claim 7. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da se korak d) sastoji od mehaničke obrade u skladu s patentnim zahtjevima 5 do 9 i obrade s jednim ili više kemijskih sredstava u skladu s patentnim zahtjevom 11.
or a salt of such a compound. A compound of formula (I) according to any one of claims 1 to 8, wherein R1 represents phenyl, which is unsubstituted, mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, (C1-C4)alkyl, (C1-C4)alkoxy, trifluoromethyl, trifluoromethoxy, and dimethylamino; 
Spoj formule (I) prema bilo kojem zahtjevu 1 do 8, naznačen time, da R' predstavlja fenil, koji je nesupstituiran, mono- ili di-supstituiran, pri čemu su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-Cy)alkil, (C;-Cy)alkoksi, trifluorometil, trifluorometoksi i dimetilamino; ili sol takvoga spoja.
The use of dopamelanin, and/or its precursors and/or its analogous and/or its derivatives, as an additive of the cement mixture that substitutes the capillary water proportion in the cement mixture. 
Uporaba dopamelanina, naznačena time, da je on aditiv u cementnoj smjesi koji zamjenjuje udio kapilarne vode u cementnoj smjesi.
The salt of any one of claims 12-14 and 17-19, wherein the salt has a powder X-ray diffraction pattern comprising: one or more or two or more or three peaks at diffraction angles (2θ) selected from the group consisting of 7.5 ± 0.2, 11.3 ± 0.2, and 24.3 ± 0.2 obtained using copper K-alpha1 X-rays at a wavelength of 1.5406 Ångstroms; a solid state NMR spectrum comprising one or more or two or more or three 13C chemical shifts selected from the group consisting of 171.3 ± 0.2, 112.4 ± 0.2, and 43.8 ± 0.2 ppm; and a solid state NMR spectrum comprising a 19F chemical shift at -123.1 ± 0.2 ppm. 
Sol prema bilo kojem od zahtjeva 12 do 14 i 17 do 19, naznačena time, da sol ima uzorak difrakcije praha X-zraka koji sadrži jednu ili više ili dvije ili više ili tri vršne vrijednosti s difrakcijskim kutevima (2θ) odabranima iz skupine koja se sastoji od 7,5 ± 0,2, 11,3 ± 0,2 i 24,3 ± 0,2, koji se dobiva uporabom bakar-K-a1-X-zraka valne duljine od 1,5406 Angstroma; gdje kruto stanje NMR spektra sadrži jedan ili više ili dva ili više ili tri 13C-kemijska pomaka odabrana iz skupine koja se sastoji od 171,3 ± 0,2, 112,4 ± 0,2 i 43,8 ± 0,2 ppm; i kruto stanje NMR spektra sadrži 19F-kemijski pomak na -123,1 ± 0,2 ppm.
A method for the treatment of a disease related to 5-HT6 receptor where said disease is schizophrenia, comprising the step of administering to a patient in need thereof an effective amount of a compound according to claim 3 . 
Spoj formule (II) prema patentnom zahtjevu 3, za proizvodnju lijeka za liječenje poremećaja središnjeg živčanog sustava povezanog s ili pogođenog s 5-HT6 receptorima.
Composition according to claim 1, wherein the red blood cells (1) contain an antigen and (2) are heat-treated or chemically treated so as to promote phagocytosis of said red blood cells by dendritic cells. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da crvene krvne stanice (1) sadrže antigen i (2) toplinski su obrađene ili kemijski obrađene tako da potiču fagocitozu navedenih crvenih krvnih stanica putem dendritskih stanica.
That application describes organic nitrates capable of providing a potent vasodilating effect and which at the same time show a small or null tolerance effect. 
Ova prijava opisuje organske nitrate koji mogu osigurati jaki vazodilatacijski učinak i koji u isto vrijeme pokazuju mali ili nulti učinak tolerancije.
a homeopathic composition in the amount of 10-75% w/w; and 
(ii) homeopatski pripravak prisutan u količini od 10-75% w/w, i
The process according to claim 1, wherein the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid is selected from the group consisting of boric acid, citric acid, sodium dihydrogen citrate, potassium dihydrogen citrate, disodium hydrogen citrate, dipotassium hydrogen citrate, sodium dihydrogen borate, potassium dihydrogen borate, disodium hydrogen borate, dipotassium hydrogen borate and mixtures thereof. 
Površinski reaktivni kalcijev karbonat koji je dobiven postupkom prema bilo kojem od zahtjeva 1 do 20, naznačen time da površina djelomično reagira sa slabim kiselinama koje su odabrane od borne kiseline, limunske kiseline, natrijevog dihidrogcn citrata, kalijevog dihidrogen citrata, dinatrijevog hidrogcn citrata, dikalijevog hidrogen citrata, natrijevog dihidrogen borata, kalijevog dihidrogen borata, dinatrijevog hidrogen borata, dikalijevog hidrogen borata i njihovih mješavina, te karbonat ima specifičnu površinu prema BET-u od više od 50 m"/g, još poželjnije više od 60 m/g i najpoželjnije više od 80 m?/g.
A compound of the formula I or a salt thereof, wherein 
Spoj, naznačen time, da je to spoj formule I:
Use of crumbles comprising at least one calcium carbonate-containing material according to any one of claims 1 to 4 in paper making, paper coating, food, plastic, preferably films, more preferably blown films or breathable films, fibres, polyvinyl chloride, plastisols, thermosetting polymers, more preferably thermosetting unsaturated polyesters or thermosetting unsaturated polyurethanes, agricultural, paint, coatings, adhesives, sealants, pharmaceuticals, agricultural, construction and/or cosmetic applications. 
Uporaba mrvica koje sadrže barem jedan materijal koji sadrži kalcijev karbonat prema bilo kojem od zahtjeva 1 do 4, naznačena time da se koristi za proizvodnju papira, premazivanje papira, prehrambene primjene, plastiku, poljoprivrednu primjenu, primjenu za boje, premaze, ljepila, brtvila, lijekove, poljoprivredne, građevinske i/ili kozmetičke primjene.
A pharmaceutical formulation according to any one of claims 1 to 4 comprising an anti-IL-17 antibody at a concentration of 80 mg/mL, citrate buffer at a concentration of 20 mM, sodium chloride at a concentration of 200 mM, polysorbate-80 at a concentration of 0.03%, and pH at 5.7, wherein the anti-IL-17 antibody comprises an antibody comprising two light chains (LCs) and two heavy chains (HCs), wherein each LC is the amino acid sequence of SEQ ID NO: 4 and each HC is the amino acid sequence of SEQ ID NO: 5. 
Farmaceutska formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što sadrži protutijelo protiv IL-17 u koncentraciji od 80 mg/ml, citratni pufer u koncentraciji od 20 mM, natrijev klorid u koncentraciji od 200 mM, polisorbat-80 u koncentraciji od 0,03%, te pH od 5,7, gdje protutijelo protiv IL-17 sadrži protutijelo koje sadrži dva laka lanca (LC) i dva teška lanca (HC), gdje svaki LC ima aminokiselinski slijed sa SEQ ID NO: 4, a svaki HC ima aminokiselinski slijed sa SEQ ID NO: 5.
The invention furthers relates to coating compositions comprising fatty acids or derivatives thereof as well as substrates with coatings obtained by heat curing of such coating compositions. 
Izum se odnosi, nadalje, na sastav premaza koji sadrži masne kiseline ili njihove derivate, kao također i na podloge s prevlakama koje su dobivene toplinskim otvrdnjavanjem takovih sastava premaza.
Examples of coating polymer suspensions comprise basic butylated methacrylate copolymer, sodium lauryl sulfate, stearic acid and purified water. 
Primjeri suspenzija s polimernim presvlakama sastoje se iz bazičnog butiliranog metakrilatnog kopolimera, natrijevog lauril sulfata, stearinske kiseline i pročišćene vode.
modulating the first 3 c and the at least one second 3 d data pseudo-streams through a first 5 and at least one second 6 modulators, respectively; 
modulacije navedenog prvog (3c) i navedenog najmanje jednog drugog (3d) pseudo-toka podataka preko prvog (5) i najmanje jednog drugog (6) modulatora, redom;
Crystalline Form II of the compound of formula I characterized by an X-ray powder diffraction pattern comprising 2θ angle values of about 11.9; about 13.4; about 13.9; about 14.6; about 15.3; about 16.4; about 17.4; about 18.8; about 19.0; about 19.5; about 21.1; about 22.7. 
Kristalna Forma II spoja formule I, naznačena time što profil difrakcije X zraka u praškastom uzorku obuhvaća vrijednosti 20 kuteva od oko 11.9; oko 13.4; oko 13.9; oko 14.6; oko 15.3; oko 16.4; oko 17.4; oko 18.8; oko 19.0; oko 19.5; oko 21.1; oko 22.7.
a water gas shift step d3) carried out on the effluent obtained from step d2), 
* korak promjene voda plin d3) koji se provodi na efluentu dobivenom u koraku d2),
The anti-cancer vaccine according to any of claims 1 to 5, further comprising at least one suitable adjuvant. 
Farmaceutski sastav sukladno bilo kojoj od tvrdnji 10 do 14, nadalje sadrži barem jedno prikladno pomoćno sredstvo.
In another embodiment the invention is a compound of formula (I) according to statement 1 wherein the optionally substituted aryl group is phenyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je izborno supstituirana arilna skupina fenil.
The method of claim 7, wherein the variable regions of the 1st and the 2nd CH3 domain-comprising polypeptide chains recognize different target epitopes, whereas the variable regions of the 3rd and the 4th CH3 domain-comprising polypeptide chains recognize the same target epitopes. 
Postupak u skladu patentnim zahtjevom 7, naznačen time što varijabilne regije prvog i drugog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju različite ciljne epitope, pri čemu varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju iste ciljne epitope.
The combination for use according to any one of claims 1 to 10, wherein said therapeutically effective amount of 5-HT3 antagonist comprises from about 0.25 to about 0.75 mg. of palonosetron or a pharmaceutically acceptable salt thereof. 
Farmaceutski pripravak prema patentnim zahtjevima 1-6, naznačen time što navedena terapeutski efikasna količina antagonista 5-HT3sadrži od oko 0.25 do oko 0.75 mg palonosetrona ili njegove farmaceutski prihvatljive soli.
An electromagnetic relay assembly (10), the electromagnetic relay assembly (10) comprising: 
Elektromagnetski relejni sklop (10) za omogućavanje selektivnog prolaženja struje kroz preklopne terminale (11), gdje elektromagnetski relejni sklop sadrži:
X is a carboxylic acid or a derivative thereof wherein the derivative is a carboxylic ester, a carboxamide, a monoglyceride, a diglyceride, a triglyceride, or a phospholipid; 
X je karboksilna kiselina ili njen derivat pri čemu je derivat karboksilni ester, karboksamid, monoglicerid, diglicerid, triglicerid ili fosfolipid;
A process according to claim 4 which further comprises the step of preparing a compound of formula Va from a compound of formula Vb, which process comprises treating said compound of formula Vb with (a) ethyl chloroformate and triethylamine to form a mixed anhydride; and (b) reacting said mixed anhydride with an amine salt NHR3R4.HCl. 
NR3R4 Vb Va gdje se navedeni postupak sastoji u obradi navedenog spoja formule Vb (a) etil-klorformijatom i trietilaminom kako bi se dobilo miješani anhidrid; i (b) reakciji navedenog miješanog anhidrida s aminskom solju NHR*R*HCI.
A combination of enteric coating polymers may also be used. 
Također se može koistiti i kombinacija polimera za eneričko oblaganje.
an air inlet and an air outlet connected with the casing; 
ulaz zraka (121) i izlaz zraka (122), spojene s kućištem (11);
The process of claim 1, wherein the curing agent is heat treated or filter sterilized after the predetermined amount of nitrite is produced. The process of any preceding claim, wherein the plant material is selected from the group consisting of celery, beet, cabbage, cucumber, eggplant, mushroom, lettuce, squash, zucchini, mixed salad greens, carrot, artichoke, green beans, lima beans, broccoli, cauliflower, collard greens, corn, mustard, okra, onion, Chinese pea pods, black eyed peas, green peas, potatoes, turnips, radishes, and combinations thereof. 
Postupak prema zahtjevu 1, gdje se tvar za sušenje toplinski obrađuje ili sterilizira filtracijom nakon što se proizvede unaprijed određena količina nitrita, Postupak prema bilo kojem od prethodnih zahtjeva, gdje se biljni materijal odabire iz skupine koju čine celer, cikla, kupus, krastavac, patlidžan, gljive, salata, bundeva, tikvica, miješane zelene salate, mrkva, artičoka, mahune, grah lima, brokula, cvjetača, kelj, kukuruz, gorušica, okra, luk, kineski zimski grašak, crnooki grašak, zeleni grašak, krumpir, repa, rotkvice i njihove kombinacije.
A still further option could be that bottle 20B contain just water. 
Slijedeća bi opcija bila da boca 20B sadrži samo vodu.
sucrose in an amount of from about 5% to about 10% w/v; and 
saharozu u količini od 5 % do 10 % w/v; i
The process of claim 1, wherein the particle number ratio between the water soluble and/or water swellable material particles and the substantially water insoluble polymer particles of the mixing step is in a range of from 1:10 to 1:100, or from 1:20 to 1:80. 
Postupak sukladno zahtjevu 1, naznačeno time, da se brojčani odnos čestica topivih materijalnih čestica, koje bubre u vodi i u vodi potpuno netopivih polimernih čestica u koraku miješanja, u tom području od 1:10 do 1:100, ili od 1:20 do 1:80.
Said composition may optionally further comprise a second therapeutic agent selected from, for example, an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti-infective agent, a targeting agent, or an adjunct compound. 
Oblik prema zahtjevu 31, koji dalje sadrži terapijsko sredstvo izabrano između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže 1 inhibira taj inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja.
Investigation of the Pharmacokinetics of H2L1 and 2E7 
Broj objave europskog patenta:
allows a handling of (human) tissue samples of different amounts and MHC expression levels, i.e. can be readily applied to primary tissue samples; 
Metoda prema zahtjevu 1, gdje navedena metoda dopušta rukovanje uzorcima tkiva različitih količina i razina ekspresije MHC.
A process for the preparation of compounds of formula (I) as defined in Claim 1, in free or salt form, which comprises the steps of: (i) 
Postupak za pripravu spojeva formule (I) definiranih kao u zahtjevu 1, u slobodnom obliku ili u obliku soli, naznačen time, da on obuhvaća slijedeće stupnjeve:
The coating of any one of claim 10 to 14 produced from an aqueous slurry, wherein the aluminum powder comprises a particle size distribution characterized in that the 50th percentile of the particle size distribution has a diameter of between about 3.9 to 4.5 microns and the 90th percentile of the particle size distribution has a diameter of less than or equal to about 9.0 microns. 
Sastav obloge iz patentnog zahtjeva 7, pri čemu prah aluminija obuhvaća raspodjelu veličina čestica karakteriziranu na način da 50. percentila raspodjele veličine čestica ima promjer između 3.9 1 4.5 mikrometara i 90. percentila raspodjele veličine čestica ima promjer manji ili jednak 9.0 mikrometara.
FIG. 2 is a schematic side-view according to line II-II of the sanding element from FIG. 
Slika 2 je shematski prikaz elementa za brušenje iz slike 1 u presjeku II-II, gledan s bočne strane.
wherein at least one of the regions A1-1, A1-2, A2-1, A2-2, A3-1, or A3-2 comprises a heterologous moiety; and wherein the recombinant FVIII protein exhibits procoagulant activity, and 
pri čemu barem jedna od regija A1-1, A1-2, A2-1, A2-2, A3-1, A3-2 ili a3 sadrži heterologni dio; i pri čemu rekombinantni FVIII protein pokazuje prokoagulantsku aktivnost.
The composition according to claim 8, for use for treating CMT, a toxic neuropathy or amyotrophic lateral sclerosis. 
Sastav iz patentnog zahtjeva 5, za uporabu u liječenju CMT1A u subjekta sisavca.